These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35430568)

  • 1. Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions.
    Massimino M; Stella S; Micale G; Motta L; Pavone G; Broggi G; Piombino E; Magro G; Soto Parra HJ; Manzella L; Vigneri P
    Cancer Genomics Proteomics; 2022; 19(3):350-361. PubMed ID: 35430568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
    Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic mutation analysis in melanoma using targeted next generation sequencing.
    Miraflor AP; de Abreu FB; Peterson JD; Turner SA; Amos CI; Tsongalis GJ; Yan S
    Exp Mol Pathol; 2017 Oct; 103(2):172-177. PubMed ID: 28822769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
    Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
    Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach.
    Manca A; Paliogiannis P; Colombino M; Casula M; Lissia A; Botti G; Caracò C; Ascierto PA; Sini MC; Palomba G; Pisano M; ; ; Doneddu V; Cossu A; Palmieri G;
    J Transl Med; 2019 Aug; 17(1):289. PubMed ID: 31455347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of an NGS mutation detection panel for melanoma.
    Reiman A; Kikuchi H; Scocchia D; Smith P; Tsang YW; Snead D; Cree IA
    BMC Cancer; 2017 Feb; 17(1):150. PubMed ID: 28228113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
    Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.
    Boussemart L; Nelson A; Wong M; Ross JS; Sosman J; Mehnert J; Daniels G; Kendra K; Ali SM; Miller VA; Schrock AB
    Oncologist; 2019 May; 24(5):657-663. PubMed ID: 30683711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of distinct molecular profile of Primary Dermal Melanoma.
    Shaigany S; Tessier-Cloutier B; Busam KJ; Horst BA
    Hum Pathol; 2020 Dec; 106():32-38. PubMed ID: 32946880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
    Silva JM; Bulman C; McMahon M
    Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma.
    Franczak C; Salleron J; Dubois C; Filhine-Trésarrieu P; Leroux A; Merlin JL; Harlé A
    Mol Diagn Ther; 2017 Apr; 21(2):209-216. PubMed ID: 28130756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
    Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G;
    BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
    Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Application of Next-Generation Sequencing-Based Panel to
    Park C; Kim M; Kim MJ; Kim H; Ock CY; Keam B; Kim TM; Kim DW; Kim JI; Heo DS
    Mol Cancer Ther; 2020 Mar; 19(3):937-944. PubMed ID: 31826932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the Diagnostic Yield of Targeted Next-Generation Sequencing for Melanoma and Gastrointestinal Tumors.
    Garg S; Grenier S; Misyura M; Sukhai MA; Thomas M; Kamel-Reid S; Stockley T
    J Mol Diagn; 2020 Apr; 22(4):467-475. PubMed ID: 32036084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma.
    Zhu ML; Zhou L; Sadri N
    Virchows Arch; 2018 Sep; 473(3):371-377. PubMed ID: 29926184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.
    Wheler J; Yelensky R; Falchook G; Kim KB; Hwu P; Tsimberidou AM; Stephens PJ; Hong D; Cronin MT; Kurzrock R
    BMC Cancer; 2015 Feb; 15():61. PubMed ID: 25886620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
    Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
    Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.